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Evaluation of serum iron overload,
AST:ALT ratio and log10ferritin:AST ratio
among schizophrenia patients in the Kumasi
Metropolis, Ghana: a case–control study
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Christian Obirikorang1, Enoch Odame Anto1,2, Emmanuel Acheampong1,2 and Sampson Donkor1*

Abstract
Objective: The association between unbalanced iron indices and the conditions of schizophrenia are not well understood. Liver dysfunction which has been linked to iron metabolism might be a contributing factor. This case–control
study evaluated serum iron indices and liver function in treatment-naïve schizophrenia patients and those already on
treatment at the Psychiatric Department of the Komfo Anokye Teaching Hospital (KATH), Kumasi-Ghana.
Results: The mean age of the respondents was 39.6 ± 0.8 years. Increased levels of serum iron, TS, AST, ALT and
AST:ALT ratio and lower levels of UIBC, TIBC, Transferrin, and log Ferritin:AST ratio levels were observed among the
treatment-naïve group compared to the control. The treatment-naïve and treatment groups showed significantly
higher serum AST:ALT ratio, and lower log10ferrtin:AST ratio than the healthy controls. There was a significant correlation between log10ferritin and AST, and log10ferritin and GGT in both treatments (r = 0.343; p = 0.003, and r = 0.502;
p = 0.001 respectively) and treatment-naïve groups (r = 0.348; p = 0.002, and r = 0.614; p < 0.001 respectively). Percentage transferrin saturation correlated significantly with GGT only, in the treatment-naïve group (r = 0.667; p < 0.001),
and ALT and GGT in the treatment group (r = 0.252; p = 0.030 and r = 0.646; p = 0.014 respectively).
Keywords: Iron overload, Schizophrenia, AST:ALT ratio, log10ferritin:AST
Introduction
According to the World Health Organization (WHO)
[1], mental disorders account for five of the ten leading
causes of disability and premature death worldwide, of
which neuropsychiatric condition accounts for 13% of
the total disability adjusted life years [1]. A prevalence
based rate report from the World Mental Health Survey
2004, undertaken by WHO in Ghana estimated that, 13%
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of the adult population suffer from some form of mental
disorder [2].
Studies in Ghana have indicated that schizophrenia is
the leading psychiatric condition [3, 4]. Owiredu et al. [5]
in their study in Ghana reported a prevalence of 59% for
schizophrenia compared to other psychiatric conditions [5].
Serious mental illness is accompanied by higher morbidity
and mortality rates of chronic diseases such as lung disease,
diabetes and liver problems [6]. A previous study found that
liver dysfunction is particularly elevated in adults with mental illness [7]. Iron overload has been reported to be significantly associated with liver damage [8].
Iron overload (IO) has been reported to be associated with
parenchymal and organ dysfunction following abnormal
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deposition of tissue iron [9, 10]. Dangers of IO in several
disease conditions over the years including coronary disease
[10–12], diabetes mellitus [10, 13], sexual impotence [9, 10],
cerebral ischemic disease [10, 14] and neurologic or psychiatric alterations [10, 15] has been noted.
The manifestations of neuropsychiatric effects of
chronic iron overload have been observed in depressives,
memory loss, paranoia, visual hallucination, lethargy,
disorientation, dementia, and anxiety symptoms [16, 17].
However, the pathophysiology of iron metabolism in psychiatric illnesses still remains unclear, albeit several studies have suggested a possible link between serum iron
and some variables in psychiatric conditions [16, 18].
There is dearth of data on serum iron indices among
psychiatric patients in Ghana, and the association
between iron overload and primary psychiatric illness.
Also, little is known about the liver function of psychiatric patients in Ghana. This study therefore evaluated
serum iron indices and liver function among schizophrenia patients in a Ghanaian population.

Main text
Methods
Study population and setting

This case–control study was carried out at the Psychiatric department of the Komfo Anokye Teaching Hospital,
Kumasi-Ghana. Qualifying patients attending the psychiatric department were recruited into the study using International classification of Diseases (ICD-10). Healthy control
participants were recruited from a keep fit club. A total of
200 participants comprising 75 treatment-naïve schizophrenia patients, 75 schizophrenia patients on treatment and 50
healthy controls were recruited via purposive sampling.
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illness were included in the study. All respondents
were ≥ 18 years.
Exclusion criteria

Schizophrenia patients already on iron therapy, non-steroidal anti-inflammatory agents, antacids, alcohol consumption, pain killers such as paracetamol etc., multiple
blood transfusions and androgen/oestrogen therapy were
all excluded from the study.
Questionnaire administration and sample collection

A validated questionnaire was administered to all
respondents by qualified nurses to collect demographic
data including age and gender. About 4 ml of venous
blood sample was collected from the antecubital fosa of
the study participants after an overnight fast, and sera
were obtained after centrifugation.Assayparameters
included: serum iron, unsaturated iron binding capacity
(UIBC), total iron binding capacity (TIBC), transferrin,
ferritin, percentage transferrin saturation, aspartate aminotransferase (AST), gamma glutamyl transferase (GGT)
and alanine aminotransferase (ALT). AST, GGT and ALT
were performed on a fully automated Mindray BS-380
auto-analyzer (Shenzhen Mindray Bio-medical electronics Co., Ltd, China). Ferritin was performed on M
 indray®
microplate reader MR 96 A. The assay for UIBC and
iron were performed on the Mindray BA-88A Biochemistry auto-analyzer. Transferrin concentration was estimated according to Vernet [19] and Gambino et al. [20]
equation.
Statistical analysis

The study was approved by the Committee on Human
Research, Publications and Ethics (CHRPE), and the
Research and Development Unit of the Komfo Anokye
Teaching Hospital (KATH). Written informed consent
was obtained from each participant through their legally
authorised family members before enrolment into the
study. All data obtained from participants was held under
strict confidentiality.

Results are presented as mean ± SD. Analysis of variance
(ANOVA) coupled with Tukey’s post hoc multiple comparisons was used to compare more than two means of
continuous variables. Unpaired t-test was used to compare the means of two continuous variables. Chi-square
test was used to assess the associations between categorized variables. Partial Pearson correlation was performed to test for associations between iron indices and
liver function markers. A p-value < 0.05 was considered
statistically significant for all analyzed data. Statistical
analyses were performed using GraphPad Prism 7.

Inclusion criteria

Results

Ethical consideration

Newly diagnosed naïve schizophrenia patients and those
already on any form of antipsychotic, such as olanzapine,
haloperidol, risperidone etc., were included in the study.
Age and sex-matched healthy individuals who were not
on any medication (antibiotics, vitamins supplement),
non-alcoholic, Tuberculosis free, HIV free, Hepatitis B
virus free, and were not presenting any signs of chronic

Table 1 shows demographic characteristics of age and
gender of the study participants. Out of the total 200
participants, 104 (52%) were females and 96 (48%)
were males. The mean age of the study population
was 39.6 years. There was no significant difference
between the mean age of the control group compared
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Table 1 Demographic characteristics of the study participants
‡

TN (n = 75)

0.4654

38.9 ± 1.4

Variables

Total (n = 200)

Control (n = 50)

T (n = 75)

Age (years)

39.6 ± 0.8

40.5 ± 1.4

39.0 ± 1.3

Male

96 (48.0%)

26 (52.0%)

34 (45.3%)

36 (48.0%)

Female

104 (52.0%)

24 (48.0%)

41 (54.7%)

39 (52.0%)

Gender

p-value

0.4723

#

p-value

0.412
0.7169

Values are presented as mean ± standard deviation (SD) and frequency (proportion) where appropriate
T treatment, TN treatment naïve

‡

p-value (comparison between control and treatment)

#

p-value (comparison between control and treatment naïve)

to the treatment (p = 0.4654) and treatment-naïve group
(p = 0.4120).
Serum iron concentration and percentage transferrin
saturation were significantly higher in treatment-naïve
psychiatric patients compared to the control (p < 0.0001).
Mean levels of transferrin, UIBC and TIBC was significantly lower in treatment-naïve psychiatric patients compared to the control (p < 0.0001). The levels of serum
ferritin was highest among the treatment-naïve group,
followed by the treatment group, and did not differ significantly compared to the control. Generally, the treatment-naïve group recorded the highest mean AST, ALT
and GGT levels, followed by the treatment group. There
was a statistically significant difference between the AST
and GGT levels of the treatment-naïve group and that of
the control group (p = 0.0035 and 0.0418 respectively).

Both the treatment-naïve and treatment groups had
higher mean AST:ALT ratio (1.61; p = 0.0004 and 1.50;
p = 0.0282 respectively) than the control group (1.29).
However, mean log ferritin:AST ratio decreased significantly from the control (0.096) to treatment group (0.084,
p = 0.0448) and then to the treatment-naïve group (0.080;
p = 0.0113) (Table 2).
Table 3 shows the biochemical profile of the study population stratified by gender. There was no statistical difference between any biochemical parameter and gender
among the control group. Both males and females in the
treatment and treatment-naïve groups reported higher
mean levels of iron, transferrin saturation, ALT, GGT
and AST but lower levels of UIBC rather than the control group. The male respondents of the treatment-naïve
group showed significantly higher mean serum iron,

Table 2 Biochemical profile of the study participants
Variables

Total (n = 200)

Control (N = 50)

T (n = 75)

‡

p-value

TN (N = 75)

#

p-value

Markers of iron overload
Serum iron (µmol/l)
Serum UIBC (µmol/l)
Serum TIBC (µmol/l)
Serum ferritin (ng/ml)
log10 (ferritin)
Serum transferrin (g/l)
% transferrin saturation
Markers of liver function
Serum AST (U/l)
Serum ALT (U/l)
GGT (U/l)
AST:ALT ratio
log10ferrtin:AST ratio

37.2 ± 1.1

60.9 ± 1.6

31.3 ± 1.8

69.6 ± 2.1

95.2 ± 2.4

100.9 ± 3.7

1.8 ± 0.0

1.8 ± 0.1

92.1 ± 5.1

3.8 ± 0.1

33.5 ± 1.4

66.2 ± 2.5

99.6 ± 3.4

0.3519
0.2846
0.5374

81.6 ± 7.5

94.3 ± 8.2

0.2827

4.02 ± 0.1

3.9 ± 0.1

0.3761

1.9 ± 0.0

0.5674

44.9 ± 1.8

40.0 ± 2.5

84.9 ± 3.1

97.0 ± 10.9
1.9 ± 0.0

3.4 ± 0.1

< 0.0001
< 0.0001
< 0.0001
0.2956
0.3975
< 0.0001

39.2 ± 0.8

31.01 ± 0.9

33.6 ± 1.0

0.3145

52.9 ± 1.6

< 0.0001

24.7 ± 0.9

20.9 ± 1.2

23.9 ± 1.2

0.0773

28.0 ± 1.8

0.0035

29.3 ± 1.8

21.32 ± 1.3

29.7 ± 1.9

0.0503

36.98 ± 2.4

0.0418

0.087 ± 0.0

0.096 ± 0.0

0.084 ± 0.0

0.0448

0.080 ± 0.0

0.0113

17.9 ± 0.6

1.5 ± 0.0

17.8 ± 1.4

1.29 ± 0.0

17.4 ± 0.8

0.8240

1.50 ± 0.1

0.0282

Values are presented as mean ± standard deviation (SD) and frequency (proportion) where appropriate

18.5 ± 1.1

1.61 ± 0.1

0.6570
0.0004

UIBC unsaturated iron binding capacity, TIBC total iron binding capacity, AST aspartate aminotransferase, ALT alanine aminotransferase, T treatment, GGT gammaglutamyl transferase, TN treatment naïve
‡

p-value (comparison between control and treatment)

#

p-value (comparison between control and treatment naïve)
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Tables 3 Biochemical profile of study population in relation to gender
Parameter

Control

p-value T

Males (n = 26) Females
(n = 24)
Iron (µmol/l)
UIBC (µmol/l)
TIBC (µmol/l)
log10ferritin
STfR (µmol/l)
%T. saturation

26.53 ± 2.8

ALT (U/l)
GGT

Male (n = 34) Female (n = 41)
0.0921

‡

36.33 ± 2.01$

42.12 ± 4.40

39.76 ± 3.35

0.0604

‡

0.7190

‡

1.72 ± 0.05

59.03 ± 4.03

1.71 ± 0.07

0.0807
0.0899

44.88 ± 1.16

2.35 ± 0.13

44.52 ± 2.64

0.9132

‡

17.92 ± 1.80

17.17 ± 1.01

0.0512

‡

0.0668

‡

21.10 ± 1.6

20.31 ± 1.4

0.0701

‡

60.65 ± 5.7

2.29 ± 0. 18

Markers of liver function
AST (U/l)

25.66 ± 1.69

p-value TN

15.50 ± 2.07

14.79 ± 1.63

$

26.46 ± 3.6

67.14 ± 2.65$
‡

2.00 ± 0.04$
4.12 ± 0.16$

#

30.82 ± 1.99$$

34.97 ± 1.7

23.03 ± 0.85$
$

18.09 ± 1.17
29.81 ± 1.9$

Male (n = 36) Female (n = 39)
0.0573

‡

#

$$

0.5290

‡

#

61.03 ± 3.01$$

0.7330

‡

#

#

3.83 ± 0.21$$

0.2977

$$

0.1092

‡

24.78 ± 2.00$$

0.4558

#

25.18 ± 2.99

#

1.72 ± 0.06$$

‡

$

p-value

#

32.02 ± 1.34

#
#

$$

16.88 ± 1.12

#

28.12 ± 1.3$$

0.0005

52.68 ± 2.75
39.63 ± 4.02
75.96 ± 2.87
‡

33.04 ± 5.34
63.86 ± 2.61
#

1.97 ± 0.05

‡

5.13 ± 0.23

35.85 ± 1.89

#

1.76 ± 0.05

< 0.0001
< 0.0001
0.0026
0.0035

4.05 ± 0.12

< 0.0001

#

58.74 ± 2.64

0.1188

‡

#
#

25.69 ± 1.66

0.1756

0.4593

‡

0.6311

‡

#

35.21 ± 2.0

0.5571

63.56 ± 1.76
30.53 ± 3.21
19.31 ± 1.83
36.81 ± 2.3

17.82 ± 1.23

0.4967

Values are presented as mean ± standard deviation (SD)
T treatment, TN treatment naïve

‡

p<0.05 for comparison between male control and male T or TN group)

#

p < 0.05 for comparison between female control and female T or TN group

$

p<0.05 for comparison between male T and male TN group

$$

p<0.05 for comparison between male T male TN group

UIBC and STfR (p < 0.0001 each), as well as higher TIBC
(p = 0.0026) and log10ferritin (p = 0.0035) rather than
their female counterparts. There was no significant difference among gender with respect to the liver function
parameters, albeit the males showed higher mean levels
of AST, ALT and GGT. With the exception of the comparable means of log10ferritn between the female treatment group and the female controls, all gender-matched
comparisons across the various groups were statistically
significant (p < 0.05).
Additional file 1: Table S1 shows the association
between iron indices and liver function parameters
among both treatment and treatment-naïve schizophrenia patients. There was a positive and significant correlation between log10ferritin and AST, and log10ferritin
and GGT in both treatments (r = 0.343; p = 0.003, and
r = 0.502; p = 0.001 respectively) and treatment-naïve
groups (r = 0.348; p = 0.002, and r = 0.614; p < 0.001
respectively). Also, percentage transferrin saturation correlated significantly with GGT only, in the treatmentnaïve group (r = 0.667; p < 0.001), and ALT and GGT in
the treatment group (r = 0.252; p = 0.030 and r = 0.646;
p = 0.014 respectively). See Additional file 1.
Discussion

In this study, the females constituted 54.7% of the treatment group. Similarly, in the treatment-naïve group,
there were more females (52.0%) than males (48.0%).
Owiredu et al. [5] also observed that higher prevalence of
psychiatric disorders were associated with females than

males in Ghana [5]. Moreover in a study by Oyane et al.
[21], the female gender was more predisposed to factors
of psychiatric disorders [21]. The increased female prevalence observed in the current study can be attributed to
the fact that, women are emotionally and psychologically
fragile in nature and are known to often internalize and
brood over problems compared to men [22].
Consistent with the findings of Ikeda [23], this present study observed significantly higher serum levels of
iron and percentage transferrin saturation among the
treatment-naïve group compared to the treatment and
control groups [23]. Moreover, the lower levels of UIBC
observed among the treatment psychiatric group and
the significantly lower UIBC recorded for the treatmentnaïve group also confirms the findings of Ikeda [23], who
observed similar levels among epileptic conditions compared to their control counterpart [23].
In agreement with the fact that the liver is the main
storage reserve of iron and is significantly affected by
excess iron [8, 24], the treatment-naïve group in the current study presented significantly higher AST and GGT
levels compared to the control group. Significantly higher
AST/ALT ratio was also associated with the treatmentnaïve patients compared to the controls, but the levels
were comparable to the treatment group. AST/ALT ratio
greater than 2:1 and increased GGT levels have been
implicated in liver damage [25].
Numerous studies using experimental hepatic
iron overload have identified iron-dependent oxidative damage and associated impairment of
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membrane-dependent functions of the mitochondria, microsomes, and lysosomes [26, 27]. Thus ironinduced lipid peroxidation occurs in hepatocytes and
increases the risk of hepatocellular injury [28, 29].
Moreover, the current study recorded significantly
lower log ferritin/AST ratio in both the treatmentnaïve and treatment groups compared to the control.
These significantly lower ratios among both groups
may be attributed to the likelihood of liver dysfunction
secondary to iron overload [8, 30].
A previous retrospective review by Feifel and Young
[15] reported increased plasma iron levels of greater
than 170 μg/dl; transferrin saturation greater than
50% and serum ferritin greater than 450 ng/ml among
patients with bipolar disorder [15]. Iron dysregulation and overload have also been implicated in Parkinson’s disease [31], Alzheimer’s disease and dementia
[32, 33]. Compared to the control group, both males
and females in the treatment group reported relatively
higher mean levels of iron, transferrin saturation, ALT,
GGT and AST, but lower levels of UIBC in the present
study. With the exception of AST, ALT and GGT levels,
a similar trend observed among the treatment-naïve
group revealed significant differences (p < 0.001) in
relation to gender. Abnormal serum ferritin (> 300 μg/l
in men and > 120 μg/l in women), and transferrin saturation (> 50%) have been reported by Cutler in a case
study among psychiatric patients [34], which is consistent with the findings in the current study.
A significant positive correlation between log10ferritin
and AST, and log10ferritin and GGT was observed in
both treatment and treatment-naïve groups. This partially agrees with a previous study by Barut et al. [35]
which also reported a positive correlation between ferritin and AST levels. This association has been implicated in certain disease conditions such as liver damage
[36], malignancy and infection [37]. Moreover, the current study recorded a significant positive correlation
between percentage transferrin saturation and GGT
only, in the treatment-naïve group, and both ALT and
GGT in the treatment group. The association of ferritin
and transferrin saturation with the liver function markers suggests that iron metabolism may be associated
with liver damage in mental illness [38].
Conclusion

Iron overload is common among schizophrenia patients
in Ghana, and the iron indices are associated with AST/
ALT ratio and log Ferritin:AST ratio within treatmentnaïve patients. The response of these biological markers has clinical implication on liver performance; thus
a possible future risk of fibrosis, mutagenesis and
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carcinogenesis. This emerging syndemic among schizophrenia patients in Ghana therefore necessitates baseline and periodic medical assessment of iron indices as
standard components in the management plans for psychiatric patients.

Limitations
The current study could not provide information on
other potential confounding factors such as Body Mass
Index (BMI), menstruation and diet patterns, and hence
should be considered in future investigations” With the
smaller sample size obtained in this case–control study,
only a temporal relationship between iron overload and
liver dysfunctions can be established. A further larger
longitudinal study is warranted to validate this syndemic relationship among schizophrenics.
Supplementary information
Supplementary information accompanies this paper at https://doi.
org/10.1186/s13104-019-4847-2.
Additional file 1: Table S1. Partial Pearson correlation between Iron
markers and liver function markers among study participants.
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